Skip to main content

W8MD services


W8MD offers the following services

W8MD physician medical weight loss, sleep, holistic and aesthetic medicine programs can help you not only to lose weight, and sleep better but also to look your best! 

Medical Weight Loss 


 Physician supervised 
 Accept most insurances 
 Delicious meal replacements 
 Appetite suppressants 
 Amazing success stories 

Sleep Medicine 


 Sleep apnea 
 Restless legs syndrome 
 Insomnia 
 Hypersomnia 
 Circadian rhythm disorders and more 
 Convenient home sleep studies 

MedSpa & IV Nutrition

 
 IV Therapy - B12, Vit C, B, Detox… 
Hair reduction 
 Body contouring Cellulite reduction 
 Laser skin resurfacing Botox & fillers 
 IPL photofacials PRP therapy 
 Microneedling & O2 facials 

W8MD weight loss, sleep and medspa centers locations

W8MD’s NYC Weight Loss, Sleep & Medspa
Manhattan, NY – 401 E 55th Street New York, NY 10022
Poly-Tech Sleep, W8MD Weight Loss & MedSpa – King of Prussia, PA
 Coming soon – W8MD Weight Loss, Sleep & Medical Spa Cherry Hill, NJ

Comments

Popular posts from this blog

What you need to know about new weight loss medication Belviq

After a long gap of over 13 years, the FDA started approving new weight loss medications beginning with Belviq approved in June of 2012 and Qsymia approved in July 2012. After a gap of another 2 years, the FDA approved two new weight loss medications in late 2014 with Contrave approved in September and Saxenda in December. Let us review these 4 new weight loss medications and compare their relative utility in helping one lose weight!


First new weight loss drug - Belviq 

Of the four new weight loss drugs, Belviq is probably one of the safest albeit not the most potent! Since it is not a stimulant type medication, it can safely be used even in those that have had a prior history of certain cardiovascular problems in the remote past including coronary artery disease.


When was Belviq approved for weight loss?

The U.S. approved Belviq (lorcaserin hydrochloride), in June of 2012 in addition to a reduced-calorie diet and exercise, for chronic weight management.


What are the indications for Bel…

Prediabetes and diabetes

The Epidemic of Prediabetes and Diabetes!
According to a new study, investigators say diabetes and prediabetes will also account for an estimated 10 percent of total health care spending by the end of the decade at an annual cost of almost $500 billion. That's up from an estimated $194 billion in 2010.

The report, "The United States of Diabetes: Challenges and Opportunities in the Decade Ahead," was unveiled this week, because November is National Diabetes Prevention month. The study offers solutions designed to improve health and life expectancy, while also saving up to $250 billion over the next 10 years.

Read this report on CNN titled Diabetes or prediabetes predicted for half of Americans by 2020

What is Prediabetes and why is it important to reverse it for weight loss, and prevention of diabetes?Prediabetes is a serious health condition that increases the risk of developing type 2 diabetes, heart disease, and stroke. Yet the vast majority of people with prediabetes do …

Belviq weight loss doctor Philadelphia

The new weight loss medication, Belviq, will be available for obesity treatment from 06/11/2013 and W8MD Medical Weight Loss Centers weight loss physicians in New York City, and Philadelphia help.

More than one-third of U.S. adults are obese, and obesity contributes to a number of health conditions, including high blood pressure, type 2 diabetes, and high cholesterol.

To help obese and overweight Americans who have been unsuccessful in getting their weight under control with diet and exercise, the Food and Drug Administration (FDA) has approved two new medications—the first drugs for long-term weight management that FDA has approved in 13 years.

Marketed as Belviq and Qsymia, these prescription medications would be taken for the rest of a person’s life. “For many people, obesity is a lifelong condition, but we don’t always think of it—or treat it—as such,” says Amy Egan, M.D., M.P.H., deputy director for safety in FDA’s Division of Metabolism and Endocrinology Products (DMEP).

“Qsymi…